27 May 2014 Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Director's Dealing
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, a director, has today purchased 210,000 ordinary shares of 0.1 pence each in the Company at a price of 20.5 pence per share.
David Evans now holds 289,033 ordinary shares of 0.1 pence each, representing 1.03 per cent. of the Company's issued share capital.
|
Enquiries: |
|
|
Venn Life Sciences Holdings Plc |
|
|
Tony Richardson, Chief Executive Officer |
Tel: +353 154 99 341 |
|
Zeus Capital Limited (Nominated Adviser and Broker) |
|
|
Ross Andrews/Andrew Jones (Corporate Finance) |
Tel: 0161 831 1512 |
|
Dominic Wilson (Institutional Sales) |
Tel: 020 7533 7727 |
|
Walbrook PR Ltd Paul McManus |
Tel: 020 7933 8787 or venn@walbrookpr.com Mob: 07980 541 893 |
|
Lianne Cawthorne |
Mob: 07584 391 303 |
This information is provided by RNS